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Abstract
Withaferin A (WA), a steroidal lactone derived from the plant Vassobia breviflora, has been
reported to have anti-proliferative, pro-apoptotic, and anti-angiogenic properties against cancer
growth. In this study, we identified several key underlying mechanisms of anticancer action of
WA in glioblastoma cells. WA was found to inhibit proliferation by inducing a dose-dependent
G2/M cell cycle arrest and promoting cell death through both intrinsic and extrinsic apoptotic
pathways. This was accompanied by an inhibitory shift in the Akt/mTOR signaling pathway
which included diminished expression and/or phosphorylation of Akt, mTOR, p70 S6K, and p85
S6K with increased activation of AMPKα and the tumor suppressor tuberin/TSC2. Alterations in
proteins of the MAPK pathway and cell surface receptors like EGFR, Her2/ErbB2, and c-Met
were also observed. WA induced an N-acetyl-L-cysteinerepressible enhancement in cellular
oxidative potential/stress with subsequent induction of a heat shock stress response primarily
through HSP70, HSP32, and HSP27 upregulation and HSF1 downregulation. Taken together, we
suggest that WA may represent a promising chemotherapeutic candidate in glioblastoma therapy
warranting further translational evaluation.
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1. Introduction
Malignant gliomas, including the grade IV astrocytoma glioblastoma multiforme (GBM),
accounting for 60–70% of such lesions, are the most common adult primary malignant brain
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tumors, representing approximately 14,000 new cancer cases yearly [1]. The mean post-
diagnosis survival time of patients with GBM is approximately 14 months [1; 2]. Most high
grade brain tumors are quite infiltrative, resulting in residual invasive tumor cells even after
optimal surgical resection. This significantly contributes to the high rate of recurrence and
poor clinical outcomes associated with this disease [3]. Standard-of-care management
typically involves surgical debulking followed by treatment with radiation and the
methylating agent temozolomide. While this currently represents the most efficacious
therapy for prolonging survival, tumors are often quick to develop resistance to this line of
therapy [4; 5]. Recent investigational therapies have yielded only modest response rates up
to 15% at best without impact on 6-month progression-free survival [1; 4].
Therefore, given a lack of current therapeutic strategies to extend survival in glioma
patients, there is a critical need for novel therapeutic agents. We previously screened over
200 natural plant extracts with promising anti-tumor potential and identified a 28-carbon
steroidal lactone obtained from the Vassobia breviflora, withaferin A (WA), with intriguing
cytotoxic properties [6]. WA has been identified as a novel cancer therapy with anti-
proliferative, proapoptotic, and anti-angiogenic properties as well as a modulator of several
key cell-survival and regulatory pathways including those involving Akt, Notch-1, heat
shock protein (HSP) 90, NFkappaB, AP-1, estrogen receptor, RET, and p38 among others
[7; 8; 9; 10; 11; 12; 13; 14; 15; 16]. Additionally, WA has shown promising anti-tumor
activity in several murine xenograft and/or orthograft models including prostate, breast,
medullary thyroid, melanoma, uveal melanoma, ovarian, cervical, and brain cancers [15; 17;
18; 19; 20; 21; 22; 23].
We have recently demonstrated the anti-proliferative effects of WA in malignant glioma
[24; 25], and this finding was subsequently confirmed demonstrating the thiol-reactivity of
WA and its ability to induce a heat shock response via a reporter assay [23]. Several
additional reports have identified the pro-oxidant potential of WA [26; 27; 28; 29], however,
the mechanism of WA’s diverse and widespread effects, especially in glioma cells, is largely
unknown. Here, we expand on previous findings to further delineate the nature of WA’s
anti-cancer effects in glioblastoma and examine the molecular response by the cell.
2. Materials and Methods
2.1 Cell culture and general reagents
Two human glioblastoma multiforme cell lines, U87 and U251, were generously provided
by Dr. Jann Sarkaria (Mayo Clinic, Rochester, MN), and one murine GBM cell line, GL26,
was graciously donated by Dr. John Ohlfest (University of Minnesota, Minneapolis, MN).
All cell lines were grown in Dulbecco’s modified Eagle’s media (DMEM #6429; Sigma-
Aldrich, St. Louis, MO) supplemented with 10% fetal bovine serum (FBS; Sigma- Aldrich,
St. Louis, MO) and 1% penicillin/streptomycin (Sigma-Aldrich, St. Louis, MO) at a 37°C
humidified atmosphere of 5% CO2 in air. Withaferin A was extracted and isolated as
previously described with a purity of 99% by HPLC and stored as a stock solution, adjusted
for impurities, at 20mM in DMSO at −80°C [6]. Propidium iodide (PI), RNase, and N-
acetyl-L-cysteine (NAC) were acquired from Sigma-Aldrich (St. Louis, MO), and Annexin
VFITC was obtained from BD Biosciences (San Diego, CA).
2.2 Cell proliferation and viability assays
Cells were seeded in 96-well plates at 2,500 cells/well. Following a 6h incubation period,
WA-containing media in various concentrations was added to each well, and the cells were
incubated for an additional 72h. The number of viable cells was quantified by the
colorometric CellTiter96 Aqueous MTS assay (Promega, Fitchburg, WI) at 490nm on a
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BioTek Synergy 2 plate reader (BioTek, Winooski, VT) as per the manufacturer’s
instructions.
Because of the non-enzymatic, auto-reductive potential of NAC, the MTS assay was unable
to be utilized for evaluating WA/NAC co-treatment studies given the nature of the assay
mechanism, as described by the manufacturer. As such, the CellTiter-Glo luminescent assay
(Promega, Fitchburg, WI) was utilized instead to measure cell viability by ATP levels. Cells
were plated in 96-well plates followed by treatment with NAC after 6h and WA 1h later.
After 72h, assay reagent was prepared as per the instructions, and 50uL was added to each
well. The luminescent signal was given 10–20 minutes to equilibrate and quantified by the
BioTek Synergy 2 plate reader.
2.3 Cell cycle analysis
Cells were plated at an amount previously determined, based on the growth characteristics
of individual cells, to have a high enough yield without achieving complete confluency upon
harvest and were allowed to grow overnight. Cells were treated with appropriate
concentrations of WA and, where indicated, pre-treated with 5mM NAC. Upon the
completion of treatment, cells were trypsinized, collected, resuspended in 0.43mL of 4°C 1x
PBS followed by 1mL of −20°C ethanol for a 70% ethanol fixative solution, and stored at
−20°C. To analyze, stored cells were collected by centrifugation, resuspended in 1x PBS
containing 40ug/mL PI and 100ug/mL RNase, and incubated at −37°C for 30 minutes before
being analyzed by flow cytometry (BD LSRII; Becton Dickinson, San Diego, CA). Analysis
of these results examined only viable cells without DNA fragmentation to establish the
distribution of the true cell cycle in living cells.
2.4 Analysis of cell death
Staining phosphatidylserine on the outer leaflet of the cell membranes on apoptotic cells and
DNA staining by PI in necrotic and late apoptotic cells was performed to assess WA-
induced cell death. Cells were plated and treated as indicated for cell cycle analysis. Upon
the completion of treatment, cells were trypsinized, collected, and washed once in Annexin
binding buffer (150mM NaCl, 5mM KCl,1mM MgCl2·6H2O, 1.8mM CaCl2·2H2O, 10mM
HEPES, and 2% (v/v) FBS). Cells were stained with Annexin V-FITC and PI according to
the manufacturer’s instructions (BD Biosciences, San Diego, CA) for 20 minutes at 4°C
before being washed twice and resuspended in binding buffer. Cells were immediately
analyzed by flow cytometry on a BD LSRII.
2.5 Western blotting
Cells were plated and treated in the manner outlined for cell cycle analysis. Proteins were
collected, quantified, separated by sodium dodecyl sulfate–polyacrylamide gel
electrophoresis (SDS–PAGE), and electrotransfered onto a Hybond nitrocellulose membrane
as previously described in Samadi, et al. [30]. Actin levels were assessed to ensure equal
loading and transfer of proteins. All studies were repeated for accuracy.
Primary rabbit antibodies against poly(ADP-ribose) polymerase (PARP; #9542; 1:1000),
caspase 3 (#9665; 1:1000), caspase 7 (#9492; 1:1000), caspase 9 (#9502; 1:1000), cyclin B1
(#4138; 1:2000), p-ERK1/2 (Thr202/Tyr204; #4377; 1:1000), Akt (#9272; 1:1000), p-Akt
(Ser473; #4058; 1:1000), c-Met (#4560; 1:500), p-c- Met (Tyr1234/1235; #3077; 1:500),
epidermal growth factor receptor (EGFR; #4267; 1:1000), p70 S6 kinase (#2708; 1:500), p-
p70 S6 kinase (Thr389; #9234; 1:1000), mTOR (#2972; 1:1000), p-mTOR (Ser2448; #2971;
1:1000), Her2/ErbB2 (#2165; 1:1000), 4E-BP1 (#9644; 1:1000); p-4E-BP1 (Thr37/46;
#2855; 1:1000), tuberin/TSC2 (#4308; 1:1000), p-tuberin/TSC2 (Thr1462; #3617; 1:1000),
AMPKα (#2603; 1:1000), and p-AMPKα (Thr172; #2535; 1:1000) and primary mouse
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antibodies against HSP27 (#2402; 1:2000), caspase 8 (#9746; 1:1000), and p-EGFR
(Tyr1068; #2236; 1:1000) were acquired from Cell Signaling Technology (Beverly, MA).
Total- and phosphoantibodies against p70 S6 kinase were used to detect p85 S6 kinase
(phospho-Thr412) given the known crossreactivity of the antibodies. Rabbit antibodies
against HSP90 (SPA-836; 1:1000), HSP32/heme oxygenase 1 (SPA- 894; 1:1000), and heat
shock factor 1 (HSF1; ADI-SPA-901; 1:1000) were acquired from Enzo Life Sciences
(Farmingdale, NY) or its affiliates along with the rat antibody for Grp94 (SPA-850; 1:1000)
and the mouse antibody for HSP70 (ADI-SPA-810; 1:1000). The mouse antibody Trap1
(MA1-010; 1:1000) was purchased from Affinity Bioreagents (Pierce Biotechnology,
Rockford, IL). A mouse total actin antibody (MAB1501; 1:50,000) to be used as a control
was acquired from EMD Millipore (Billerica, MA). A mouse antibody against Raf-1
(sc-7267; 1:250), a goat antibody against p-Raf-1 (Ser338; sc-12358; 1:250), and a rabbit
antibody against ERK1/2 (sc-154; 1:5000) were obtained from Santa Cruz Biotechnology
(Santa Cruz, CA). Donkey anti-rabbit IgG HRP (sc-2313; 1:5000), goat antimouse IgG HRP
(sc-2005; 1:5000), and goat anti-rat IgG HRP (sc-2032; 1:5000) secondary antibodies were
also purchased from Santa Cruz Biotechnology. Given primary antibody species specificity,
Western analysis was completed in the human U87 and U251 cells lines.
2.6 Detection of ROS
The accumulation of intracellular reactive oxygen species, particularly peroxides like H2O2,
was determined using CM-H2DCFDA (Molecular Probes, Grand Island, NY), a general
oxidative stress indicator that fluoresces upon oxidation. Cells were preloaded with 20uM
CM-H2DCFDA in 1x dPBS at 37°C for 1h, washed once with phenol redfree DMEM
containing 10% FBS and 1% penicillin/streptomycin, and plated in 96-well plates in phenol
red-free media at 40,000 cells/well for GL26 and 20,000 cells/well for U87. After 30
minutes, cells were treated with WA, NAC, or both. Measurements were taken on a BioTek
Synergy 2 plate reader at 4h with excitation and emission filters of 485nm and 528nm,
respectively.
Detection of mitochondrial superoxide present at a given timepoint was examined by
MitoSOX Red (Molecular Probes, Grand Island, NY), an indicator reagent that fluoresces
upon oxidation by superoxide radicals. Cells were plated and allowed to attach and grow
overnight. Pre-treatment with 5mM NAC occurred 1h before treatment with 5uM WA. Cells
were harvested 4h after WA addition, washed once with 1x dPBS, and stained with 5uM
MitoSOX Red in 1x dPBS for 30 minutes at 37°C. Cells were washed twice with 1x dPBS
and run on a BD LSRII flow cytometer (Becton Dickinson, San Diego, CA) with excitation
and emission filters of 488nm and 580nm, respectively, to assess mean fluorescence
intensity.
2.7 Statistical analysis
GraphPad (GraphPad Inc., San Diego, CA) was used to generate best-fit sigmoidal dose
response curves for IC50 determination. Comparisons of differences between two or more
means were determined by Student’s unpaired t-test (2 means) via a standard statistical
analysis software package (SPSS version 17.0; SPSS Inc, Chicago, IL). The level of
significance was set at p<0.05. Data are presented as mean values with error bars denoting
standard deviation. All studies were minimally performed in triplicate unless otherwise
noted.
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3.1 Withaferin A reduces cell proliferation and viability in GBM cells
To investigate the general biological effect of withaferin A in glioblastoma cells, three cell
lines (U87, U251, and GL26) were incubated with increasing concentrations of WA or a
DMSO control for 72h. Cell number and viability were subsequently determined by using
the MTS assay (Fig. 1). WA dose escalation reduced cell proliferation and viability. By
GraphPad analysis, the IC50 values of WA were determined to be 1.07±0.071µM,
0.69±0.041µM, and 0.23±0.015µM for U87, U251, and GL26 cells, respectively.
3.2 Withaferin A induces G2/M cell cycle arrest in GBM cells in a dose-dependent manner
In order to establish the nature of the anti-proliferative response to WA, distribution of the
cell cycle phases of glioblastoma cells was assessed by flow cytometry at 24h. WA induced
a dose-dependent shift in cell cycle arrest from the G0/G1 checkpoint to G2/M arrest.
Maximal shift to G2/M arrest above baseline was observed at 0.75µM in U87 cells (12.0%
G2/M in controls increasing to 63.4% with treatment), 1.5µM in U251 cells (19.1% baseline
to 49.7% with treatment), and 0.5µM in GL26 cells (21.7% baseline to 58.7% with treatment
(Fig. 2a). Doses above these optimal levels showed a somewhat diminished G2/M cell cycle
shift. The shift to G2/M cell cycle arrest is accompanied by a depletion of cells in the G0/G1
phase and a relative increase in S phase as observed in the U87 (11%) and GL26 (14%),
whereas the S phase proportion in U251 cells was largely unchanged (Fig. 2a).
To confirm these findings, the G2/M-specific protein cyclin B1, which is elevated during
G2/M cell cycle arrest, was evaluated by Western blot analysis for increases in expression
with WA treatment. At 24h, both U87 and U251 cells demonstrated a dose-dependent
induction of cyclin B1 expression with maximal expression levels observed at 1µM and
2.5µM WA, respectively (Fig. 2b). Flow cytometry identified sustained G2/M cell cycle
arrest at both 48h and 72h with Western analysis up to 48h supporting those findings (data
not shown).
3.3 Withaferin A induces GBM cell death
To further characterize the anti-proliferative effects of WA, annexin V and propidium iodide
(PI) dual staining on flow cytometry was used to evaluate the ability of WA to induce cell
death through apoptotic and necrotic mechanisms. Fig. 3a illustrates that increases in WA
concentration corresponded with enhanced cell death in U87, U251, and GL26 cells at 24h.
While all cell lines demonstrated evidence of an apoptotic response indicated by annexin V
staining, U87 cells appear to also exhibit increased levels of necrosis with treatment as
indicated by staining with PI only. From baseline measurements of 3.9–5.9%, total cell
death at 3µM WA treatment was 51.4% for U87 cells (9.0% early apoptosis; 18.4% late
apoptosis; 24.0% necrosis), 24.4% for U251 cells (12.0% early apoptosis; 9.9% late
apoptosis; 2.5% necrosis), and 31.7% for GL26 cells (4.4% early apoptosis; 22.2% late
apoptosis; 5.1% necrosis). Upon doubling the concentration to 6µM, total cell death
increased to 86.9% for U87 cells (3.4% early apoptosis; 55.5% late apoptosis; 28.0%
necrosis), 47.1% for U251 cells (9.7% early apoptosis; 32.5% late apoptosis; 4.9% necrosis),
and 83.1% for GL26 cells (0.6% early apoptosis; 74.1% late apoptosis; 8.4% necrosis).
Further induction of apoptosis was observed at 48h (data not shown).
In order to confirm that these cells were undergoing an apoptotic response, protein levels of
mitochondrial/intrinsic procaspase 9, extrinsic procaspase 8, effector procaspases 3 and 7,
and downstream PARP cleavage were examined by Western blotting (Fig. 3b). With
increasing concentrations of WA, a reduction in the levels of all uncleaved caspases was
observed at 5µM in both U87 and U251 cells at 24h. Procaspases 3, 7, and 8 demonstrated
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reduced levels at WA concentrations below 5uM in U87 cells. Finally, PARP cleavage was
observed at both 2.5 and 5µM WA in both U87 and U251 cell lines. These data confirm that
WA-mediated cytotoxicity at concentrations above IC50 is in part due to induction of
apoptosis in these GBM cells.
3.4 Withaferin A alters normal protein expression and activation in the Akt/mTOR and
MAPK pathways
Given the inhibition of proliferation and induction of cell death observed with WA
treatment, several proteins associated with the Akt/mTOR and mitogen-activated protein
kinase (MAPK) growth, proliferation, and survival pathways as well as key surface
membrane proteins that signal to each pathway, known to be important in glioma and other
cancers [1], were screened in U87 and U251 cells for total expression and activation via
phosphorylation status at 24h post-treatment (Fig. 4). Total levels of Akt and mTOR were
reduced with increasing concentrations of WA. Akt and mTOR phosphorylation were dose-
dependently diminished in U87 cells, but only p-mTOR was decreased in U251 cells. Total
levels of p70 S6 kinase (downstream of mTOR) and its nuclear isoform p85 S6 kinase were
largely unchanged in both cell lines with enhanced downregulation only observed in p85
S6K at 5µM WA in U87 cells. Lowdose WA induced phosphorylation of both proteins, but
this was reduced and/or further depleted upon achieving levels of 0.5µM WA and above.
Expression of total levels of the translation-repressor 4E-BP1 (also downstream of mTOR)
was markedly increased in U87 cells with elevated levels of inhibitory phosphorylation upon
increasing WA concentration. In contrast, U251 cells exhibited decreased levels of both total
and phosphorylated forms of 4E-BP1 with WA treatment suggesting an overall inhibitory
alteration to the Akt/mTOR signaling pathway. Negative regulator of the pathway, AMPKα,
was sustained or upregulated in total levels at all WA concentrations tested with the
exception of 5µM in U87 cells. Another negative regulator, the tumor suppressor tuberin/
TSC2, was sustained in U87 cells and upregulated in U251 cells up to 1µM WA before
diminishing at increased concentrations. However, activation of both tuberin/TSC2 and
AMPKα via phosphorylation was observed at WA levels as low as 0.1–0.25µM and
maintained at higher doses. Peak levels were observed between 0.5–2.5µM in a cell-
dependent manner.
Next, the effect of WA on the MAPK cascade was assessed since others have previously
implicated WA as an inducer of a MAPK-mediated stress response [6; 12]. In the U87 and
U251 cells, total levels of ERK1/2 were unchanged with WA treatment over 24h, but p-
ERK1/2 levels were elevated with increasing concentrations of WA up to 2.5µM and then
diminished at 5µM (Fig. 4). In contrast to U87 cells, which express both p-ERK1 and p-
ERK2 at comparable levels with treatment, p-ERK2 predominates expression with WA
treatment of U251 cells. Additionally, total levels of upstream Raf-1 were diminished at
2.5–5µM WA but activation of this protein by phosphorylation of serine 338 was observed
in a dose-dependent manner with increasing WA concentrations.
EGFR, Her2/ErbB2, and c-Met are commonly amplified and/or mutated surface proteins in
glioblastoma and signal both the MAPK and AKT/mTOR pathways. As such attempts have,
previous attempts have been made to therapeutically target these proteins [31; 32; 33; 34;
35]. In both GBM cell lines, total levels of EGFR, Her2/ErbB2, and c-Met were decreased at
24h with increasing WA levels with the exception of c-Met upregulation from 0.25–2.5µM
WA (Fig. 4). Phosphorylation of EGFR increased with WA treatment, whereas c-Met
phosphorylation was slightly elevated over controls at low WA doses but was
downregulated at higher WA concentrations.
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3.5 Withaferin A elevates pro-oxidant potential in GBM cells and induces a cellular
oxidative stress response
WA-induced apoptosis in several cancer types was recently described as being mediated by
reactive oxygen species (ROS) generation [26; 27; 28; 29]. Given the role ROS are known
to play in a variety of cancer chemotherapeutic agents [36; 37; 38], we examined whether
the oxidation status of glioblastoma cells was altered by WA. The production of peroxide-
type radicals with CM-H2DCFDA and mitochondrial accumulation of superoxide radicals
with MitoSOX Red was measured in U87 and GL26 cells at 4h post-WA exposure. GL26
and U87 cell lines demonstrated elevated oxidation status in response to increasing
concentrations of WA. Peroxides rose 29.4% in GL26 cells (p=0.01) and 90.5% in U87 cells
(p=0.003) compared to controls (Fig. 5a) while mitochondrial superoxide increased 10.9%
(p=0.002) and 10.8% (p=0.03) above control at 5µM, respectively (Fig. 5b). In order to
determine the nature of this response, cells were simultaneously incubated with 5mM of the
thiol antioxidant N-acetyl-Lcysteine (NAC), described as both a redox buffer and ROS
scavenger [27; 39]. NAC significantly reduced peroxide generation in WA-treated cells and
returned levels to near-baseline in both GL26 cells (p=0.006) and U87 cells (p=0.001). NAC
reduced levels of mitochondrial superoxide radicals but failed to do so within statistical
significance, and levels remained significantly elevated in U87 cells, despite being reduced
compared to WA-alone. Induction of a heat shock response was also recently described in
cells via a luminescence reporter assay following WA exposure [23]. Consistent with other
models of oxidative stress [40; 41], we observed that WA modulates heat shock protein
expression levels at both 24h and 48h in U87 and U251 cells (Fig. 5c). While total levels of
HSP90 and its isoforms Trap1 and GRP94 were not consistently or significantly altered with
changing WA concentration, HSP70 and HSP32 (heme oxygenase 1) were markedly
upregulated while HSF-1 was potently downregulated with increasing WA concentration in
both a dose-dependent and time-dependent manner (Fig. 5c and 5d). Dose-dependent
reduction of HSF1 corresponded with an increase in the higher molecular weight
phosphorylated fraction of the total protein remaining. Moderate induction of HSP27 was
observed predominantly at 48h with cell line-dependent diminished expression at 5µM, the
highest concentration examined.
3.6 Pre-treatment with a thiol-antioxidant protects GBM cells from the anti-proliferative and
cytotoxic effects of withaferin A
To determine if the elevated oxidation state induced by WA is responsible for the apoptotic
and anti-proliferative effects observed in vitro, proliferation and apoptosis in the GBM cells
were examined in the context of co-treatment with NAC. Consistent with the MTS assay
data previously generated, WA was shown to diminish cell viability in a dose dependent
manner with the highest potency being demonstrated in GL26 cells. Pre-treatment with 0.5,
1, and 5mM NAC enhanced the resulting cell viability, abrogating the anti-proliferative
effects of WA such that with 5mM NAC pretreatment, the anti-proliferative effects of WA
were completely eliminated at up to 6uM doses in the U87, U251, and GL26 cell lines (Fig.
6a).
Next, the effects of WA on both cell cycle arrest and apoptosis were evaluated by flow
cytometry in the context of NAC pretreatment. As previously described, flow cytometry
with WA was performed following 1h pretreatment with NAC in U87, U251, and GL26
cells. Analysis of the cell cycle data revealed that NAC pretreatment was able to completely
prevent cell cycle shift to G2/M arrest following 1µM WA treatment at 24h (Fig. 6b). This
was supported by a lack of dose-dependent increases in expression of cyclin B1 by Western
analysis at 24h when NAC was used in combination with WA (Fig. 6d). Furthermore, dual
staining with PI and Annexin V revealed that NAC pre-treatment completely eliminated all
dose-dependent apoptosis and necrosis associated with WA treatment (Fig. 6c). This
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observation was then confirmed by a lack of PARP cleavage associated with increasing WA
concentration when cells were pre-treated with NAC (Fig. 6d).
Finally, WA-mediated effects on heat shock response were evaluated following pretreatment
with 5mM NAC. As shown in Figure 6d, NAC pre-treatment effectively prevented induction
of HSP70 and HSP32 at 24h postexposure while limiting depletion of HSF1 following WA
treatment.
4. Discussion
Over the past decade, withaferin A has emerged as a promising anti-cancer
chemotherapeutic agent. Its effects in cancer cells have been described as anti-proliferative,
pro-apoptotic, and anti-angiogenic [7, 8; 9; 10; 11; 12; 13; 14; 15; 16]. To date, however, the
detailed mechanism of action of WA in malignant gliomas has not been wellelucidated. The
results presented in this study demonstrate for the first time that WA is effectively able to
induce a dose-dependent progression of G2/M cell cycle arrest followed by apoptosis-
mediated cell death in glioblastoma cells. Reduction in both initiator caspases 8 and 9
suggests that WA can dually activate both extrinsic and intrinsic apoptotic pathways,
consistent with previous findings in myeloid leukemia [29]. Such effects appear to be a
result of enhanced cellular oxidative stress generated by these compounds which can be
completely abrogated by pretreatment with NAC. This oxidative stress with WA treatment
also leads to induction of several heat shock proteins associated with cellular stress as well
as alteration of the MAPK and Akt/mTOR growth and proliferation pathways including
several of their corresponding surface receptors EGFR, Her2/ErbB2, and c-Met.
Pharmacological induction of oxidative stress has emerged as an intriguing means by which
to mount an anticancer effect. It is thought that pro-oxidant intervention can alter the redox
homeostasis of cancer cells, already stressed by exposure to constitutively high levels of
ROS not observed in normal cells, by shifting the balance to a state of cytotoxicity [42; 43].
In fact, many investigational chemotherapeutics with redox potential have recently been
explored in preclinical and clinical settings [36; 38]. Such an oxidative stress mechanism has
also been demonstrated to effectively induce the proteotoxic stress of protein unfolding/
misfolding, resulting in a downstream secondary cytotoxicity that likely preferentially
affects these already susceptible cancer cells that may warrant exploration in the WA model
[41; 44]. In our experiments, induction of HSP70, HSP32, and HSP27 with WA treatment
follows previous models of oxidative stress [40; 41] and lends further credence to the pro-
oxidant potential of this drug compound.
HSF1, a transcription factor that plays a major role in the expression of heat shock proteins,
has been proposed to be a potentially important target in cancer therapy [45]. While control
of HSF1, the major mediator of the observed stress response, has been well-studied,
regulation of its stability and turnover remains unclear [46]. As such, it remains unknown if
WA directly induces HSF1 degradation or if the resulting decrease in expression is due to
some cellular feedback mechanism following its role as a transcription factor to induce heat
shock protein expression. Here, we demonstrate that WA may represent a pharmacological
means by which to downregulate total HSF1 protein levels.
In contrast to studies with other cancer models, superoxide radicals do not appear to be
highly elevated in glioblastoma cells upon WA exposure as measured by MitoSOX Red
staining, however peroxide-type radicals are elevated in as detected by CM-H2DCFDA [26;
27]. As noted in Figure 5b, it is unclear if the transient but statistically significant elevation
in superoxide detected (11% in both cells lines examined) is physiologically relevant. Given
that the majority of oxidants measured are known to be potential downstream products of
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superoxide, it is possible that these GBM cells express elevated levels of enzymes like
superoxide dismutase, either inherently or as a byproduct of maintenance in cell culture [47;
48].
Our data indicate that the thiol reactivity and/or enhanced oxidation state associated with
WA treatment can be fully sequestered by NAC and is likely the main mechanism
responsible for the cytotoxic effects generated by WA, however, it remains unknown
whether WA directly releases and/or induces ROS or if its thiol-reactive properties shift the
normal balance of oxidation by altering the responsible cellular regulation. While WA has
previously been demonstrated to bind directly to thiols of certain proteins including HSP90
[9; 23], the specificity of such binding has not yet been fully explored. Given the maintained
and sometimes elevated levels of certain proteins and signaling pathways evaluated in this
study, we hypothesize that some proteins and pathways in gliomas are more susceptible to
the effects of WA, whether through direct binding or secondary effects, resulting in
dysfunction and degradation.
Although multiple groups, including ours, have demonstrated the ability of WA to
downregulate Akt signaling via its total levels and phosphorylation status in several cancer
models [6, 7; 11; 15], no reports describe its effects on other proteins in the Akt/mTOR
signaling pathway. In this study, WA shifts the balance of such signaling into an inhibitory
state, likely representing a plausible means by which the compound limits growth and
proliferation in glioma. Because the tumor suppressor phosphatase and tensin homolog
(PTEN) is inactivated by genetic alterations in approximately 60% of glioblastomas,
including the cell lines U87 and U251 [49], leading to constitutive activation of the Akt/
mTOR pathway, the relevance of targeting this pathway is important [50; 51].
Hyperactivated Akt has been shown to result in uncontrolled cell cycle progression and
protection from apoptosis [52]. Decreases in the total and phosphorylated levels of Akt,
mTOR, p70 S6 kinase, and p85 S6 kinase as observed here with WA treatment represent
direct prevention of the pathway’s proliferative effects. In the presence of cellular stress,
AMPK suppresses mTOR through phosphorylation of the tumor suppressor tuberin/TSC2 or
the mTOR subunit Raptor [53]. It has previously been shown that AMPK activation
contributes to apoptosis in glioblastoma cells [54]. Upon WA exposure, glioblastoma cells
exhibit activating phosphorylation of both tuberin/TSC2 and the catalytic alpha subunit of
AMPK.
The ability of WA to induce phosphorylation of proteins in the MAPK cascade such as
ERK1/2 and the isoforms p38 and JNK has been previously demonstrated in several other
cancer models [6; 12]. While activation of ERK is generally regarded as a pro-survival
attribute and may represent a compensatory mechanism of the cells to stress, it has also been
shown as a potential pro-apoptotic signal which may explain its role here. In this study
activation of ERK1/2 with WA treatment was observed in the setting of increasing levels of
PARP cleavage and caspase activitation. WA has previously been demonstrated to induce
apoptosis through activation of the p38 MAPK [12], so further exploration of ERK’s role in
WA-induced cell-death in gliomas is warranted.
This study provides new insight into the potent anti-cancer activity of withaferin A against
glioblastomas. The findings presented suggest that the underlying mechanism of WA’s
antiproliferative, pro-apoptotic, and cell-cycle arresting action are mainly due to its
induction of oxidative stress and a stress response by the cells leading to alterations in the
expression and signaling of several major pathways, especially the Akt/mTOR proliferative
pathway. While this drug has great potential to be a novel therapeutic for the treatment of
gliomas, future in vivo studies will determine how these mechanistic effects translate
Grogan et al. Page 9













biologically and the role of WA in clinical applications for patients with glioblastoma
multiforme.
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(A) Structure of withaferin A. (B) U87, U251, and GL26 cells were incubated with
increasing concentrations of WA or a DMSO control for 72h and then assessed by MTS
assay. WA dose escalation reduced cell proliferation and viability with IC50 values of
1.07±0.071µM, 0.69±0.041µM, and 0.23±0.015µM for U87, U251, and GL26 cells,
respectively
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(A) Cells stained with propidium iodide and analyzed by flow cytometry revealed that WA
induces a dosedependent G2/M cell cycle arrest with an optimal range of such as response at
24h. Maximal induction of arrest above baseline was observed at 0.75µM, 1.5µM, and
0.5µM for U87, U251, and GL26 cells, respectively. Adjacent histograms display
representative examples of these peak values in each cell line. (B) G2/M arrest was
confirmed by Western blotting for cyclin B1. At 24h, U87 and U251 cells demonstrated
dose-dependent induction of cyclin B1 with highest levels at 1uM and 2.5µM, respectively
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(A) Cells stained with propidium iodide and annexin V-FITC and analyzed by flow
cytometry revealed that increasing WA concentrations correspond with enhanced cell death
in U87, U251, and GL26 cells at 24h. Adjacent dot plots display representative examples of
each cell line. (B) Induction of apoptosis was confirmed by Western blotting in U87 and
U251 cell lines. WA treatment resulted in reduction in the levels of uncleaved initiator
caspases 8 and 9 as well as effector caspases 3 and 7. Further, PARP cleavage was observed
at 2.5 and 5µM in both lines
Grogan et al. Page 16














Following WA treatment, an array of proteins associated with the Akt/mTOR and MAPK
growth, proliferation, and survival pathways as well as surface membrane proteins that
signal to each pathway were screened via Western blotting in U87 and U251 cells for total
expression and activation via phosphorylation status at 24h post-exposure in order to help
evaluate the molecular changes corresponding with cellular observations. Alterations in
expression are observed in both pathways and with the cell surface receptors
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(A) Generation of peroxide-type radicals like H2O2 following exposure to increasing
concentrations of WA were quantified with CM-H2DCFDA staining in U87 and GL26 cells
at 4h. (B) Mitochondrial accumulation of superoxide radicals was assessed by flow
cytometry with MitoSOX Red staining in U87 and GL26 cells at 4h post-exposure to 5µM
WA. Elevated oxidation status observed in (A) and (B) was reduced or completely
eliminated by concurrent treatment with the thiol antioxidant N-acetyl-L-cysteine (5mM).
(C) An array of proteins associated with the heat shock stress response were screened via
Western blotting in U87 and U251 cells 24h and 48h post-treatment of WA. Upregulation
was consistently observed with HSP70 and HSP32 in a dose- and time-dependent manner (C
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and D) with alterations in other proteins displaying a cell-specific response. Expression of
the transcription factor HSF1 was decreased across both cell lines. *p < 0.05
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N-acetyl-L-cysteine effectively prevented the WA-mediated decrease in viability by the
ATP-quantifying CellTiter-Glo assay (A), G2/M cell cycle arrest by propidium iodide
staining (B), and cell death by propidium iodide/annexin V-FITC dual staining (C). (D)
These findings corresponded with Western analysis for molecular markers of G2/M arrest
(cyclin B1) and apoptosis (PARP cleavage) as well as a complete prevention of the heat
shock stress response with 5mM NAC pretreatment. *p < 0.05
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